Found: 39
Select item for more details and to access through your institution.
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 6, p. 742, doi. 10.1007/s10637-017-0445-0
- By:
- Publication type:
- Article
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-34109-8
- By:
- Publication type:
- Article
Author Correction: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
- Published in:
- Nature Communications, 2018, v. 9, p. 16187, doi. 10.1038/ncomms16187
- By:
- Publication type:
- Article
Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
- Published in:
- Nature Communications, 2017, v. 8, n. 7, p. 15987, doi. 10.1038/ncomms15987
- By:
- Publication type:
- Article
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00663-1
- By:
- Publication type:
- Article
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
- Published in:
- British Journal of Cancer, 2022, v. 126, n. 3, p. 514, doi. 10.1038/s41416-021-01536-1
- By:
- Publication type:
- Article
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
- Published in:
- European Journal of Endocrinology, 2022, v. 186, n. 6, p. 631, doi. 10.1530/eje-21-1259
- By:
- Publication type:
- Article
Mitogen-Activated Pathway Kinase Inhibitor-Associated Retinopathy: Do Features Differ with Upstream versus Downstream Inhibition?
- Published in:
- Ocular Oncology & Pathology, 2023, v. 9, n. 1/2, p. 25, doi. 10.1159/000529127
- By:
- Publication type:
- Article
Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.
- Published in:
- Current Oncology Reports, 2017, v. 19, n. 4, p. 1, doi. 10.1007/s11912-017-0587-4
- By:
- Publication type:
- Article
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
- Published in:
- Molecular Oncology, 2022, v. 16, n. 10, p. 2000, doi. 10.1002/1878-0261.13214
- By:
- Publication type:
- Article
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers.
- Published in:
- Oncologist, 2024, v. 29, n. 6, p. e779, doi. 10.1093/oncolo/oyac080
- By:
- Publication type:
- Article
A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors.
- Published in:
- Oncologist, 2021, v. 26, n. 10, p. e1844, doi. 10.1002/onco.13860
- By:
- Publication type:
- Article
Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series.
- Published in:
- Oncologist, 2021, v. 26, n. 1, p. 7, doi. 10.1634/theoncologist.2020-0379
- By:
- Publication type:
- Article
Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1178313
- By:
- Publication type:
- Article
Clinical implications of drug‐induced liver injury in early‐phase oncology clinical trials.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 22, p. 4967, doi. 10.1002/cncr.33153
- By:
- Publication type:
- Article
The METeoric rise of MET in lung cancer.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 22, p. 4826, doi. 10.1002/cncr.33159
- By:
- Publication type:
- Article
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1263, doi. 10.1007/s10637-022-01281-z
- By:
- Publication type:
- Article
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-30496-0
- By:
- Publication type:
- Article
Acute Promyelocytic Leukemia in HIV-Infected Adults: A Case Report and Review of Therapeutic Considerations.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 5, p. E47, doi. 10.3816/CLML.2010.n.075
- By:
- Publication type:
- Article
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.
- Published in:
- Therapeutics & Clinical Risk Management, 2018, v. 14, p. 1247, doi. 10.2147/TCRM.S147381
- By:
- Publication type:
- Article
Q&A: Barriers to Testing for NTRK Fusions in Metastatic Lung and Thyroid Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 16
- By:
- Publication type:
- Article
Management of Patients with NTRK Fusion-Positive Lung Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 5
- By:
- Publication type:
- Article
Efficacy and Safety of NTRK Inhibitors in Patients With NTRK Fusion-Positive Lung and Thyroid Cancers.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, p. 1
- By:
- Publication type:
- Article
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 8, p. 1796, doi. 10.1002/cam4.4579
- By:
- Publication type:
- Article
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.
- Published in:
- 2021
- By:
- Publication type:
- journal article
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
- Published in:
- Communications Biology, 2020, v. 3, n. 1, p. 1, doi. 10.1038/s42003-020-01508-w
- By:
- Publication type:
- Article
RET -Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.
- Published in:
- Cancers, 2023, v. 15, n. 16, p. 4146, doi. 10.3390/cancers15164146
- By:
- Publication type:
- Article
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3246, doi. 10.3390/cancers12113246
- By:
- Publication type:
- Article
Targeting NTRK Fusions Across Tumor Types.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 8, p. 504
- By:
- Publication type:
- Article
Systemic Approaches for Multifocal Bronchioloalve-olar Carcinoma: Is There an Appropriate Target?
- Published in:
- Oncology (08909091), 2010, v. 24, n. 10, p. 888
- By:
- Publication type:
- Article
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.
- Published in:
- OncoTargets & Therapy, 2017, v. 10, p. 1983, doi. 10.2147/OTT.S109295
- By:
- Publication type:
- Article
Extended-Duration Therapy in Advanced Non-Small-Cell Lung Cancer: Promise and Pitfalls.
- Published in:
- Clinical Lung Cancer, 2010, v. 11, n. 6, p. 383, doi. 10.3816/CLC.2010.n.050
- By:
- Publication type:
- Article
Decision‐making as discovery: Vetting clinical research in a leading precision oncology service.
- Published in:
- Sociology of Health & Illness, 2024, v. 46, n. 3, p. 495, doi. 10.1111/1467-9566.13719
- By:
- Publication type:
- Article